Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.56 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 4/20 | 0.51 |
| ▸ | DRD4 | P21917 | 4/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1024810 | 0.92 | FFAR4 (0.55) | FFAR4CHRM4DRD2DRD4FFAR1 | |
| SCHEMBL31042529 | 0.87 | CHRM4 (0.50) | FFAR4CHRM4DRD2DRD4GRM5 | |
| SCHEMBL3607872 | 0.87 | AR (0.59) | FFAR4FFAR1 | |
| SCHEMBL2559433 | 0.86 | CHRM4 (0.57) | FFAR4CHRM4DRD2DRD4GRM5 | |
| SCHEMBL31042536 | 0.86 | CHRM4 (0.57) | FFAR4CHRM4DRD2DRD4GRM5 | |
| SCHEMBL2558173 | 0.84 | FFAR4 (0.47) | FFAR4CHRM4DRD2DRD4FFAR1 | |
| SCHEMBL31042543 | 0.84 | CHRM4 (0.55) | FFAR4CHRM4DRD2DRD4GRM5 | |
| SCHEMBL30164232 | 0.82 | CHRM4 (0.56) | CHRM4DRD2DRD4GRM5DRD3 | |
| SCHEMBL7520833 | 0.82 | CHRM4 (0.49) | CHRM4DRD2DRD4GRM5DRD3 | |
| SCHEMBL31042537 | 0.82 | CHRM4 (0.46) | FFAR4CHRM4DRD2DRD4GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4660188-A1 | COMPOSITION FOR PREVENTING OR TREATING CANCER DISEASES COMPRISING ARYL-PIPERIDINE DERIVATIVE | Korea Research Institute of Chemical Technology (KR) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024162805-A1 | COMPOSITION FOR PREVENTING OR TREATING CANCER DISEASES COMPRISING ARYL-PIPERIDINE DERIVATIVE | 한국화학연구원 | 2024-08-08 | — | — | WO | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | FFAR4 2075/4885CHRM4 4834/4885DRD2 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.